| Madeline Grade, MD | |
|
505 Parnassus Ave Rm M24, San Francisco, CA 94143-2204 | |
| (415) 353-1529 | |
| Not Available |
| Full Name | Madeline Grade |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 505 Parnassus Ave Rm M24, San Francisco, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497215644 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A179218 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
With deportation and discrimination fears currently on the minds of many in the United States, a University of Michigan study shows that the stress from an historic immigration raid is associated with Latina mothers delivering babies with lower birth weights, and sometimes early.
Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.
Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.
› Verified 5 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
With deportation and discrimination fears currently on the minds of many in the United States, a University of Michigan study shows that the stress from an historic immigration raid is associated with Latina mothers delivering babies with lower birth weights, and sometimes early.
Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.
Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.
› Verified 5 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
With deportation and discrimination fears currently on the minds of many in the United States, a University of Michigan study shows that the stress from an historic immigration raid is associated with Latina mothers delivering babies with lower birth weights, and sometimes early.
Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.
Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madeline Grade, MD 505 Parnassus Ave Rm M24, San Francisco, CA 94143-2204 Ph: (415) 353-1529 | Madeline Grade, MD 505 Parnassus Ave Rm M24, San Francisco, CA 94143-2204 Ph: (415) 353-1529 |
News Archive
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
With deportation and discrimination fears currently on the minds of many in the United States, a University of Michigan study shows that the stress from an historic immigration raid is associated with Latina mothers delivering babies with lower birth weights, and sometimes early.
Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.
Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.
› Verified 5 days ago
Paul Robinson, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1230 Arguello Blvd Apt 2, San Francisco, CA 94122 Phone: 415-948-8836 | |
Frederick D Pitts Jr., MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 229 7th St, San Francisco, CA 94103 Phone: 415-503-6042 Fax: 415-503-6099 | |
Georgina Lisseth Calderon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 10th Ave, Apt. 1, San Francisco, CA 94122 Phone: 323-514-0964 | |
Timothy Bauer Duncan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2333 Buchanan St, San Francisco, CA 94115 Phone: 209-342-2300 Fax: 209-524-4240 | |
Bichhuong M Dinh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3555 Cesar Chavez, San Francisco, CA 94110 Phone: 240-447-1281 | |
Dr. Lauren Elizabeth Chalwell, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1001 Potrero Avenue Department Of Emergency Medicine, San Francisco General Hospital,, San Francisco, CA 94110 Phone: 415-206-5753 | |
Dr. Jeremy Lacocque, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Potrero Ave, San Francisco, CA 94110 Phone: 628-206-8000 |